



HSPC: hormone-sensitive prostate cancer, CRPC: castration-resistant prostate cancer, ADT: androgen deprivation therapy.

*Lymphocytes count in the fig. 4A, was extracted from different trials (cf materials and methods): n=70, HSPC pre ADT: 32, post ADT: 17 and CRPC: 21 patients.

Fig. S3